The Cineworld share price is down 85% this year! Here’s why it’s my contrarian pick

The Cineworld share price can start improving in the near future despite continued risks, making a fortune for investors.  

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

FTSE 250 cinema stock Cineworld (LSE: CINE) has had an awful 2020. The Cineworld share price is down by around 85% since last November. Entertainment venues have been hit by the double whammy of lockdowns and conservative consumer spending in these uncertain times. Yet, I don’t think it’s a stock to write off.

For one, it looks ridiculously cheap now at sub-30p levels. The way I see it, there’s little to lose in buying this FTSE 250 stock at its current share price. Sure, it might stay at these rock-bottom levels for a while, but I think it will start inching back up. Here’s why.

Better times ahead

I reckon that we’ll get some grip on coronavirus soon enough. City-wide Covid-19 testing has started in Liverpool, which returns results in 20 minutes. There’s even hope that AstraZeneca’s vaccine, currently in trial phase, can become available before the end of 2020. Even if that doesn’t happen, at the very least we can expect a vaccine sooner rather than later. Since Cineworld’s fortunes are directly linked to the lockdown, I’d expect its share price to start rising as the situation gets better.

Next, the broader economic picture is slated to improve significantly in 2021. With an improving likelihood of resolving the Covid-19 crisis, I reckon that forecasts will stay optimistic. Cineworld is a classic cyclical stock, which means that it does better when the economy’s growing and vice-versa. As things get back on track, CINE can revive as well. I like that more than half its revenues are generated in the US, which is not just the largest global consumer market, but it’s also expected to show 3.1% growth next year. 

CINE’s rising debt

However, the big danger to the Cineworld share price is liquidity. According to Fitch Ratings, it could run out of money before the end of the year. Based on this, it has also lowered the FTSE 250 cinema chain’s debt rating. It’s possible, of course, that the company may be able to manage securing more funding to keep going. 

There’s also the possibility of it becoming an acquisition target. In fact, speculation is already doing the rounds since a Chinese entrepreneur upped his stake in the business recently. But even if that were to happen, it’s unlikely that Cineworld will be valued as low as its current share price, especially given its past elevated levels.

In sum

I’m not saying that the Cineworld share price will bounce back to previous highs any time soon. In fact, that’s quite unlikely for now. It’s quite possible that it will start gaining ground, however, in the next few months. This can be as much in anticipation of improvement as on-the-ground increase in cinema activity. 

As an investor, I’m interested in how much my investments can grow. And the Cineworld share price seems to be poised for becoming a growth stock again. Risky, but growing.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Manika Premsingh owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »